Cabometyx (cabozantinib tablet)

P1, N=33, Suspended, University of Utah | Trial completion date: May 2028 --> Dec 2028 | Recruiting --> Suspended | Trial primary completion date: May 2026 --> Dec 2026

Casdatifan has shown promising clinical activity in the ARC-20 ccRCC platform study, both as monotherapy and in combination with the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib. Currently, casdatifan is being evaluated in a Phase 3 trial in combination with cabozantinib (NCT07011719) in patients with advanced ccRCC.

P3, N=5000, Not yet recruiting, Exelixis

P=N/A, N=311, Completed, Ipsen | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Oct 2025

Advanced disease shows unpredictable response to targeted therapy, underscoring the need for further molecular characterization and prospective studies to optimize management strategies. Long-term surveillance remains essential due to the risk of late recurrence.

P4, N=216, Not yet recruiting, Centro Di Riferimento Oncologico Di Aviano

P2, N=111, Recruiting, Fox Chase Cancer Center | Trial primary completion date: Feb 2026 --> Dec 2026

After progression on ate/bev, evidence across cohorts favors tyrosine kinase inhibitor strategies such as lenvatinib over sorafenib. Cabozantinib and ramucirumab (for alpha-fetoprotein ≥400 ng/mL) are options and selected patients may benefit from immune checkpoint inhibitor-based combinations...Although ate/bev has improved outcomes in uHCC, key gaps remain, including biomarkers for regimen selection, de-escalation criteria, optimal sequencing, and integration with LRT or perioperative care. Prospective studies are needed to guide practice.

Early tumor shrinkage was independently associated with the OS, suggesting its potential as a prognostic indicator in patients with mRCC treated with first-line ICI-based combination therapy.

At the 2026 ASCO GU Cancer Symposium, two randomized phase III trials evaluated earlier integration of belzutifan: LITESPARK-022 (belzutifan plus pembrolizumab vs. pembrolizumab alone in the adjuvant setting) and LITESPARK-011 (belzutifan plus lenvatinib vs. cabozantinib in the post-PD-(L)1 setting)...Together, these studies suggest that earlier targeting of HIF-2α biology may improve disease control and durability. However, patient selection, toxicity considerations, and the absence of mature OS data remain critical factors in determining the optimal role of belzutifan-based strategies across disease states.

Finally, combination therapy reduced tumor size and increased survival in mice. Our results showed that combining radiotherapy and cabozantinib reduced 4T1 tumor growth and enhanced anti-cancer immunomodulatory effects.

P1, N=44, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed